Overview of vaccine field studies: Types of effects and designs

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 4, 2006, Pages 415-427

  Halloran, M E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Efficacy; Infectious disease; Vaccine

Indexed keywords

VACCINE;

CHICKENPOX; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG APPROVAL; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; MEASLES; METHODOLOGY; MUMPS; PATHOGENESIS; PERTUSSIS; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; REVIEW; TUBERCULOSIS; VACCINATION; VALIDATION STUDY;

ANIMALS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; VACCINATION; VACCINES;

EID: 33745712469     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400600719236     Document Type: Review

References (48)

1. Becker, N. G., Britton, T., O'Neill, P. D. (2003). Estimating vaccine effects on transmission of infection from household outbreak data. Biometrics 59:467-475.
2. Chu, H., Halloran, M. E. (2004). Estimating vaccine efficacy using auxilliary outcome data and a small validation set. Statistics in Medicine 23:2697-2712.
3. Clemens, J., Brenner, R., Rao, M., Tafari, N., Lowe, C. (1996). Evaluating new vaccines for developing countries: efficacy or effectiveness? J. Am. Med. Assoc. 275:390-397.
4. Durham, L. K., Longini, I. M., Halloran, M. E., Clemens, J. D., Nizam, A., Rao, M. (1998). Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am. J. Epidemiol. 147:948-959.
5. Durham, L. K., Halloran, M. E., Longini, I. M., Manatunga, A. M. (1999). Comparison of two smoothing methods for exploring waning vaccine effects. Applied Statistics 48:395-407.
6. Farrington, C. P. (2003). On vaccine efficacy and reproduction numbers. Math Biosciences 185:89-109.
7. Fine, P. E. (1993). Herd immunity. Epidemiologic Reviews 15:265-302.
8. Fine, P. E. M., Clarkson, J. A. (1987). Reflections on the efficacy of pertussis vaccines. Rev. Inf. Dis. 9(5):866-883.
9. Fine, P. E. M., Clarkson, J. A., Miller, E. (1988). The efficacy of pertussis vaccines under conditions of household exposure: Further analysis of the 1978-80 PHLS-ERL study in 21 area health authorities in England. Int. J. Epidemiol. 17(3):635-642.
10. Fox, J. P., Hall, C. E., Elveback, L. R. (1970). Epidemiology: Man and Disease. New York: MacMillan Publishing Co, Inc.
11. Gilbert, P. B., Bosch, R. J., Hudgens, M. G. (2003). Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 59:531-541.
12. Golm, G. T., Halloran, M. E., Longini, I. M. (1999). Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials. Biometrics 55:94-101.
13. Greenwood, M., Yule, U. G. (1915). The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc. R. Soc. Med. 8(part 2):113-194.
14. Halloran, M. E., Struchiner, C. J. (1991). Study designs for dependent happenings. Epidemiology 2:331-338.
15. Halloran, M. E., Struchiner, C. J. (1995). Causal inference for infectious diseases. Epidemiology 6:142-151.
16. Halloran, M. E., Longini, I. M. (2001). Using validation sets for outcomes and exposure to infection in vaccine field studies. Am. J. Epidemiol. 154:391-398.
17. Halloran, M. E., Struchiner, C. J., Spielman, A. (1989). Modeling malaria vaccines II: Population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosc. 94:115-149.
18. Halloran, M. E., Haber, M. J., Longini, I. M. (1992). Interpretation and estimation of vaccine efficacy under heterogeneity. Am. J. Epidemiol. 136:328-343.
19. Halloran, M. E., Struchiner, C. J., Watelet, L. (1994). Epidemiologic effects of vaccines with complex effects in an age-structured population. Math Biosci. 121:193-225.
20. Halloran, M. E., Longini, I. M., Struchiner, C. J. (1996). Estimability and interpretation of vaccine efficacy using frailty mixing models. Am. J. Epidemiol. 144:83-97.
21. Halloran, M. E., Struchiner, C. J., Longini, I. M. (1997). Study designs for different efficacy and effectiveness aspects of vaccination. Am. J. Epidemiol. 146:789-803.
22. Halloran, M. E., Longini, I. M., Struchiner, C. J. (1999). Design and interpretation of vaccine field studies. Epidemiologic Reviews 21:73-88.
23. Halloran, M. E., Longini, I. M., Gaglani, M. J., Piedra, P. A., Chu, H., Herschler, G. B., Glezen, W. P. (2003a). Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am. J. Epidemiol. 158:305-311.
24. Halloran, M. E., Préziosi, M.-P., Chu, H. (2003b). Estimating vaccine efficacy from secondary attack rates. J. Am. Statist. Assoc. 98:38-46.
25. Hayes, R., Mosha, F., Nicoll, A., Grosskurth, H., Newell, J., Todd, J., Killewo, J., Rugemalila, J., Mabey, D. (1995). A community trial of the impact of improved sexually transmitted disease treatment on HIV epidemic in rural Tanzania: 1. Design. AIDS 9:919-926.
26. Hudgens, M. G., Halloran, M. E. (2006). Causal vaccine effects on binary postinfection outcomes. J. Am. Statist. Assoc. 101:51-64.
27. Hudgens, M. G., Longini, I. M., Halloran, M. E., Choopanya, K., Vanichseni, S., Kitayaporn, D., Mastro, T. D., Mock, P. A. (2001). Estimating the HIV transmission probability in injecting drug users in Thailand. Applied Statistics 50:1-14.
28. Hudgens, M. G., Hoering, A., Self, S. G. (2003). On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine 22:2281-2298.
29. Kanaan, M. N., Farrington, C. P. (2002). Estimation of waning vaccine efficacy. J. Am. Statist Assoc. 97:389-397.
30. Kendrick, P., Eldering, G. (1939). A study in active immunization against pertussis. Am. J. Hyg. Sect. B. 38:133.
31. Koopman, J. S., Little, R. J. (1995). Assessing HIV vaccine effects. Am. J. Epidemiol. 142:1113-20.
32. Lipsitch, M. (2000). Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of non-vaccine serotypes. Am. J. Epidemiol. 154:85-92.
33. Longini, I. M., Koopman, J. S. (1982). Household and community transmission parameters from final distributions of infections in households. Biometrics 38(1):115-126.
34. Longini, I. M., Halloran, M. E. (1996). A frailty mixture model for estimating vaccine efficacy. Applied Statistics 45:165-173.
35. Longini, I. M., Datta, S., Halloran, M. E. (1996). Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirus 13:440-447.
36. Monto, A. S., Davenport, J. A., Napier, J. A., Francis, T. F. (1969). Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic. Bull World Health Organ 41:537-542.
37. Moulton, L. H., O'Brien, K. L., Kohberger, R., Chang, I., Reid, R., Weatherholtz, R., Hackell, J. G., Siber, G. R., Santosham, M. (2001). Design of a group-randomised streptococcus pneumoniae vaccine trial. Contr. Clin. Trials 22:438-452.
38. O'Neill, P. O. D., Balding, D. J., Becker, N. G., Eerola, M., Mollison, D. (2000). Analyses of infectious disease data from household outbreaks by Markov chain Monte Carlo methods. Appl. Statist. 49:517-542.
39. Piedra, P. A., Gaglani, M., Herschler, G., Kozinetz, C., Riggs, M., Griffth, M., Fewlass, C., Watts, M., Hessel, C., Cordova, J., Glezen, W. P. (2005). Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23:1540-48.
40. Préziosi, M.-P., Halloran, M. E. (2003a). Effects of pertussis vaccination on severity: vaccine efficacy for clinical severity. Clinical Infectious Diseases 37:772-779.
41. Préziosi, M.-P., Halloran, M. E. (2003b). Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21:1853-1861.
42. Rhodes, P. H., Halloran, M. E., Longini, I. M. (1996). Counting process models for differentiating exposure to infection and susceptibility. J. R. Statist. Soc. B 58:751-762.
43. Ross, R. (1916). An application of the theory of probabilities to the study of a priori pathometry, Part 1. Proc. R. Soc. Series. A. 92:204-230.
44. Scharfstein, M. E., Halloran, D. O., Chu, H., Daniels, M. J. (2006). On estimation of vaccine efficacy using validation samples with selection bias. Biostatistics (in press).
45. Smith, P. G., Rodrigues, L. C., Fine, P. E. M. (1984). Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int. J. Epidemiol 13(1):87-93.
46. Struchiner, C. J., Halloran, M. E. (2006). Randomization and baseline transmission in vaccine field trials. Epidemiology and Infection (in press).
47. Struchiner, C. J., Halloran, M. E., Robins, J. M., Spielman, A. (1990). The behavior of common measures of association used to assess a vaccination program under complex disease transmission patterns - a computer simulation study of malaria vaccines. Int. J. Epidemiol. 19:187-196.
48. Struchiner, C. J., Halloran, M. E., Brunet, R. C., Ribeiro, J. M. C., Massad, E. (1994). Malaria vaccines: Lessons from field trials. Cadernos do Saúde Pública 10(supplement 2):310-326.